{"paper_id":"6124d6ff-0ea3-4cc6-9595-8106b4f9840a","body_text":"Abstract\nKeywords: Agonist, Antagonist, Ligand, Modulator, Nonsteroid, Progesterone receptor, Steroid.\nCurrent Medicinal Chemistry\nTitle:Current Progresses and Trends in the Development of Progesterone Receptor Modulators\nVolume: 23 Issue: 23\nAuthor(s): Wenlu Li, Xi Li, Bin Zhang, Chunmei Gao, Yuzong Chen and Yuyang Jiang\nAffiliation:\nKeywords: Agonist, Antagonist, Ligand, Modulator, Nonsteroid, Progesterone receptor, Steroid.\nAbstract: The progesterone receptor (PR) is a ligand-activated steroid receptor in the nuclear receptor (NR) superfamily of transcription factor. Besides gynecological and obstetrical indications, the involvement/mechanism of PR in many other diseases, such as oncology, neurology, immunology, etc. has been revealed and studied in recent decades. Therapeutic agents that selectively activate or inhibit PR have been developed. PR agonists have generally been used in oral contraception and postmenopausal hormone replacement therapy (HRT), typically in combination with estrogens. PR antagonists and selective PR modulators (SPRMs) can be useful therapies for hormone dependent breast and prostate cancers, nonmalignant chronic conditions such as fibroids, and endometriosis. This review provides an overview and detailed discussions about the recent development of chemical structures of the PR ligands, their structural characteristics (particularly those contributing to their activity and selectivity), in vitro/in vivo studies and clinical trial outcomes, and the synthetic methodologies.\nExport Options\nAbout this article\nCite this article as:\nLi Wenlu, Li Xi, Zhang Bin, Gao Chunmei, Chen Yuzong and Jiang Yuyang, Current Progresses and Trends in the Development of Progesterone Receptor Modulators, Current Medicinal Chemistry 2016; 23 (23) . https://dx.doi.org/10.2174/0929867323666160428105310\n| DOI https://dx.doi.org/10.2174/0929867323666160428105310 |\nPrint ISSN 0929-8673 |\n| Publisher Name Bentham Science Publishers |\nOnline ISSN 1875-533X |\nCall for Papers in Thematic Issues\nAdvance in Novel Drug and combined Therapies for Chronic Diseases\nChronic diseases such as malignant tumors and rheumatoid arthritis have long plagued a large number of patients. Currently, the management of chronic diseases has entered a new stage of targeted regulation, precise intervention and integrated treatment. The traditional diagnosis and treatment model is undergoing profound changes due to new drugs ...read more\nAdvances in Computational Strategies for Neurodegenerative Disorders, Cancer, and Infectious Diseases”\nThis thematic issue highlights recent advances in computational strategies applied to neurodegenerative disorders, cancer, and infectious diseases. It focuses on the use of artificial intelligence, machine learning, molecular modeling, molecular dynamics simulations, bioinformatics, and multi-omics data analysis to understand disease mechanisms and accelerate drug discovery. The contributions demonstrate how computational ...read more\nAI-Assisted Medicinal Chemistry and Bioactive Delivery Systems for Tissue Engineering and Regenerative Medicine\nThe proposed Mini-Thematic Issue aims to highlight recent advances at the interface of medicinal chemistry, artificial intelligence-assisted drug design, bioactive biomaterials, and regenerative medicine. With the rapid development of computational chemistry, quantitative structure–activity/structure–function relationship analysis, molecular docking, molecular dynamics simulation, high-throughput screening, and machine learning-based prediction models, medicinal chemistry is ...read more\nArtificial Intelligence Empowers the Research and Development of Anti-Infective Drugs: From Target Discovery and Molecular Design to Clinical Translation\nThe global crisis of drug resistance in bacteria, viruses, fungi, and parasites is becoming increasingly severe. Traditional anti-infective drug development faces bottlenecks such as long cycles, high costs, low success rates, and a shortage of novel structures. Artificial intelligence (AI) and machine learning are fundamentally reshaping the drug discovery and ...read more\n- Author Guidelines\n- Bentham Author Support Services (BASS)\n- Graphical Abstracts\n- Fabricating and Stating False Information\n- Research Misconduct\n- Post Publication Discussions and Corrections\n- Publishing Ethics and Rectitude\n- Increase Visibility of Your Article\n- Archiving Policies\n- Peer Review Workflow\n- Order Your Article Before Print\n- Promote Your Article\n- Manuscript Transfer Facility\n- Editorial Policies\n- Allegations from Whistleblowers\n- Announcements\nRelated Articles\nCurrent Cancer Drug Targets Cardiovascular Tests: Use & Limits of Biochemical Markers - Therapeutic Measurements of ADMA Involved in Cardiovascular Disorders\nCurrent Pharmaceutical Design Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification\nCurrent Topics in Medicinal Chemistry Future Oncotargets: Targeting Overexpressed Conserved Protein Targets in Androgen Independent Prostate Cancer Cell Lines\nAnti-Cancer Agents in Medicinal Chemistry Safety and Proof-of-Concept Efficacy of Inhaled Drug Loaded Nano- and Immunonanoparticles in a c-Raf Transgenic Lung Cancer Model\nCurrent Cancer Drug Targets Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials\nCurrent Pharmaceutical Design Structure Based Functional Annotation of Putative Conserved Proteins from Treponema pallidum: Search for a Potential Drug Target\nLetters in Drug Design & Discovery Evaluation of Tophaceous Gout by FDG-PET/CT and Bone Scan\nCurrent Molecular Imaging (Discontinued) TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy\nEndocrine, Metabolic & Immune Disorders - Drug Targets From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment\nAnti-Cancer Agents in Medicinal Chemistry In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging\nCurrent Radiopharmaceuticals The Metabolism of Anticancer Drugs by the Liver: Current Approaches to the Drug Development Process\nCurrent Drug Metabolism Assembling High-quality Lymph Node Clinical Target Volumes for Cervical Cancer Radiotherapy using a Deep Learning-based Approach\nCurrent Medical Imaging Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes\nCurrent Pharmaceutical Design Advances and Perspectives in Cell-Specific Aptamers\nCurrent Pharmaceutical Design Spherical Self-Organizing Map Detects MYBL 1 As Candidate Gene for Triple-Negative Breast Cancer\nNeuroscience and Biomedical Engineering (Discontinued) Recent Patents on Nanoparticles and Nanoformulations for Cancer Therapy\nRecent Patents on Drug Delivery & Formulation Systemic Delivery of Peptide Hormones Using Nasal Powders: Strategies and Future Perspectives\nDrug Delivery Letters Bone Metastases Radiopharmaceuticals: An Overview\nCurrent Radiopharmaceuticals First Inhibitors of the Steroidogenic Enzyme Type 7 17β-Hydroxysteroid Dehydrogenase\nLetters in Drug Design & Discovery","source_license":"CC0","license_restricted":false}